Table 1.

Completed clinical trials assessing the safety and efficacy of MSC therapy in ARDS.

CT Title	Trial Phase	MSC Source	Patient Status	N	Route of Administration	Endpoints	Dose	Results	Reference n°
Mesenchymal Stem Cells (MSC) for Treatment of Acute Respiratory Distress Syndrome (ARDS) in Patients with Malignancies	1	Allogeneic BM-MSC	Blood and marrow transplantation ARDS	20	Intravenous	Adverse events Clinical improvement	3 × 106 cell/Kg	No study results posted	NCT02804945
Human Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome (START)	1	Allogeneic BM-MSC	ARDS	9	Intravenous	Adverse events Ventilator and ICU free days to day 28 Hospital survival to day 60 Mortality at hospital discharge	1, 5 and 10 × 106 cells/kg predicted body weight (PBW)	Intravenous infusion of allogeneic, BM-MSC was well tolerated in patients with ARDS	NCT01775774